Portman Ltd’s Vera Therapeutics VERA Stock Holding History

Portman Ltd’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.45M	Hold	32,795	–	–	3.62%	5
2024 Q2	$1.19M	Buy	+32,795	New	+$1.3M	4.48%	2

Other funds holding VERA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Portman Ltd's VERA Position: Q3 2024 in Review

Portman Ltd held its Vera Therapeutics (VERA) position steady in Q3 2024 at 32,795 shares worth $1.45M. The position accounts for 3.62% of the portfolio, ranked #5.

Portman Ltd first reported a position in VERA in Q2 2024 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold VERA as of Q3 2024.

Portman Ltd held 32,795 shares of Vera Therapeutics worth $1.45M as of Q3 2024.
Portman Ltd left its Vera Therapeutics share count unchanged in Q3 2024.
Vera Therapeutics made up 3.62% of Portman Ltd's portfolio in Q3 2024, its #5 holding.
Portman Ltd first reported a position in Vera Therapeutics in Q2 2024 and has held it in 2 quarters since.
173 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2024.

Based on Portman Ltd's 13F filing for Q3 2024, filed 12 Nov 2024.